RE:Good clinical updateDawg this is not high finance. The cash situation has to be dire and must be addressed quickly. The science might be great but it's going to take more money just to keep the lights on. Hopefully, the solution won't be more and more dilution. All those existing warrants sitting out there have to be dealt with in any future JV or other buyout negotiations, and if more warrants get issued in this next funding, the upside begins to diminish for existing shareholders. With under $400k as of the end of the quarter, the bank account has to be low for TLT.